Contrast-induced acute kidney injury

Cardiovasc Interv Ther. 2020 Jul;35(3):209-217. doi: 10.1007/s12928-020-00660-8. Epub 2020 Apr 6.

Abstract

Although major advancements in the field of cardiology have allowed for an increasing number of patients to undergo minimally invasive imaging and interventional procedures, contrast-induced acute kidney injury (CI-AKI) continues to be a dreaded complication among patients receiving intravascular contrast media. CI-AKI is characterized by progressive decline in kidney function within a few days of contrast medium administration. Physiological changes resulting from the direct nephrotoxic effect of contrast media on tubular epithelial cells and release of vasoactive molecules have been implicated in creating a state of increased oxidative stress and subsequent ischemic renal cell injury. Over the last several years, preventive strategies involving intravenous hydration, pharmaceutical agents and renal replacement therapies have resulted in lower rates of CI-AKI. However, due to the evolving paradigm of diagnostic and therapeutic interventions, several unanswered questions remain. This review highlights the epidemiology, pathogenesis and preventive strategies of CI-AKI.

Keywords: Acute kidney injury; Contrast; Nephropathy.

Publication types

  • Review

MeSH terms

  • Acute Kidney Injury / chemically induced*
  • Acute Kidney Injury / epidemiology
  • Acute Kidney Injury / physiopathology
  • Acute Kidney Injury / prevention & control*
  • Angiography / adverse effects
  • Contrast Media / administration & dosage
  • Contrast Media / adverse effects*
  • Extravasation of Diagnostic and Therapeutic Materials / epidemiology
  • Extravasation of Diagnostic and Therapeutic Materials / physiopathology
  • Extravasation of Diagnostic and Therapeutic Materials / prevention & control*
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Incidence
  • Risk Factors
  • Tomography, Optical Coherence
  • Ultrasonography, Interventional

Substances

  • Contrast Media
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors